Skip to main content
Erschienen in: International Urogynecology Journal 8/2013

01.08.2013 | Original Article

The effect of uterine fibroid embolization on lower urinary tract symptoms

verfasst von: David Shveiky, Cheryl B. Iglesia, Danielle D. Antosh, Bela I. Kudish, Joanna Peterson, Chun-Chin Huang, James B. Spies

Erschienen in: International Urogynecology Journal | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

The objective was to determine the effect of uterine fibroid embolization (UFE) on lower urinary tract symptoms (LUTS) and quality of life (QoL).

Methods

This prospective study included women with symptomatic fibroids and LUTS who underwent UFE between March 2008 and May 2010. Subjects underwent pre-procedural pelvic magnetic resonance imaging (MRI) and completed the Urogenital Distress Inventory (UDI-6), Incontinence Impact Questionnaire (IIQ-7), Prolapse and Incontinence Sexual Questionnaire (PISQ-12), Uterine Fibroid Symptom Quality of Life questionnaire (UFS-QoL), and a standardized 48-h bladder diary at baseline and 3 months after the procedure. Patient Global Impression of Improvement (PGI-I) assessed post-procedural patient satisfaction. The primary outcome was subjective improvement in LUTS at 3 months, as measured by a decrease in UDI-6 score. Univariate analysis, paired t test and a stepwise regression analysis were appropriately conducted.

Results

Fifty-seven patients underwent UFE and completed bladder diaries and questionnaires. At 3 months after UFE, patients reported a significant decrease in UDI-6, IIQ-7, and UFS-QoL, indicating an improvement in urinary symptoms and QoL. Bladder diaries showed a significant reduction in daytime and night-time voids. No difference was found in incontinence episodes. Uterine volume, dominant fibroid size, fibroid location, and MRI-confirmed bladder compression did not affect the difference in UDI-6 scores. In a stepwise regression model, BMI had a significant impact on the change in UDI-6 score, with a decrease of 1.18 points for each 1 unit increase in BMI.

Conclusion

Uterine fibroid embolization significantly improves LUTS and urinary-related QoL. Obesity seems to attenuate this effect.
Literatur
1.
Zurück zum Zitat Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM (2003) High cumulative incidence of uterine leiomyoma on black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–107PubMedCrossRef Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM (2003) High cumulative incidence of uterine leiomyoma on black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–107PubMedCrossRef
2.
Zurück zum Zitat Wallach EE, Vlahos NF (2004) Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 104:393–406PubMedCrossRef Wallach EE, Vlahos NF (2004) Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 104:393–406PubMedCrossRef
3.
Zurück zum Zitat Flynn M, Jamison M, Datta S, Myers E (2006) Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 195:955–964PubMedCrossRef Flynn M, Jamison M, Datta S, Myers E (2006) Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 195:955–964PubMedCrossRef
4.
Zurück zum Zitat Pron G, Cohen M, Soucie J, Garvin G, Vanderburgh L, Bell S, Ontario Uterine Fibroid Embolization Collaboration Group (2003) The Ontario Uterine Fibroid Embolization Trial. I. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril 79(1):112–119PubMedCrossRef Pron G, Cohen M, Soucie J, Garvin G, Vanderburgh L, Bell S, Ontario Uterine Fibroid Embolization Collaboration Group (2003) The Ontario Uterine Fibroid Embolization Trial. I. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril 79(1):112–119PubMedCrossRef
5.
Zurück zum Zitat Learman LA, Summitt RL Jr, Varner RE, McNeeley SG, Goodman-Gruen D, Richter HE, Lin F, Showstack J, Ireland CC, Vittinghoff E, Hulley SB, Washington AE, Total or Supracervical Hysterectomy (TOSH) Research Group (2003) A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol 102(3):453–462PubMedCrossRef Learman LA, Summitt RL Jr, Varner RE, McNeeley SG, Goodman-Gruen D, Richter HE, Lin F, Showstack J, Ireland CC, Vittinghoff E, Hulley SB, Washington AE, Total or Supracervical Hysterectomy (TOSH) Research Group (2003) A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol 102(3):453–462PubMedCrossRef
6.
Zurück zum Zitat Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K, Ontario Uterine Fibroid Embolization Collaboration Group (2003) The Ontario Uterine Fibroid Embolization Trial. II. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 79(1):120–127PubMedCrossRef Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K, Ontario Uterine Fibroid Embolization Collaboration Group (2003) The Ontario Uterine Fibroid Embolization Trial. II. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 79(1):120–127PubMedCrossRef
7.
Zurück zum Zitat Spies JB, Cornell C, Wothington-Kirsch R, Lipman J, Benenati JF (2007) Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study. J Vasc Interv Radiol 18:203–207PubMedCrossRef Spies JB, Cornell C, Wothington-Kirsch R, Lipman J, Benenati JF (2007) Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study. J Vasc Interv Radiol 18:203–207PubMedCrossRef
8.
Zurück zum Zitat Bucek RA, Puchner S, Lammer J (2006) Mid- and long-term quality-of-life assessment in patients undergoing uterine fibroid embolization. AJR Am J Roentgenol 186(3):877–882PubMedCrossRef Bucek RA, Puchner S, Lammer J (2006) Mid- and long-term quality-of-life assessment in patients undergoing uterine fibroid embolization. AJR Am J Roentgenol 186(3):877–882PubMedCrossRef
9.
Zurück zum Zitat Spies JB, Cooper JM, Worthington-Kirsch R, Lipman J, Mills BB, Benenati JF (2004) Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol 191:22–31PubMedCrossRef Spies JB, Cooper JM, Worthington-Kirsch R, Lipman J, Mills BB, Benenati JF (2004) Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol 191:22–31PubMedCrossRef
10.
Zurück zum Zitat Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S et al (2008) Uterine artery embolization for treatment of leiomyomata long-term outcomes from the FIBROID Registry. Obstet Gynecol 111(1):22–33PubMedCrossRef Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S et al (2008) Uterine artery embolization for treatment of leiomyomata long-term outcomes from the FIBROID Registry. Obstet Gynecol 111(1):22–33PubMedCrossRef
11.
Zurück zum Zitat Barber MD, Walters MD, Bump RC (2005) Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 193:103–113PubMedCrossRef Barber MD, Walters MD, Bump RC (2005) Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 193:103–113PubMedCrossRef
12.
Zurück zum Zitat Rogers R, Kammerer-Doak D, Villarreal A, Coates K, Qualls C (2001) A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol 184:552–558PubMedCrossRef Rogers R, Kammerer-Doak D, Villarreal A, Coates K, Qualls C (2001) A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol 184:552–558PubMedCrossRef
13.
Zurück zum Zitat Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM (2002) The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99(2):290–300PubMedCrossRef Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM (2002) The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99(2):290–300PubMedCrossRef
14.
Zurück zum Zitat Harding G, Coyne KS, Thompson CL, Spies JB (2008) The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes 6:99PubMedCrossRef Harding G, Coyne KS, Thompson CL, Spies JB (2008) The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes 6:99PubMedCrossRef
15.
Zurück zum Zitat Barber MD, Spino C, Janz NK, Brubaker L, Nygaard I, Nager CW, Wheeler TL (2009) The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. Am J Obstet Gynecol 200(5):580.e1–580.e7CrossRef Barber MD, Spino C, Janz NK, Brubaker L, Nygaard I, Nager CW, Wheeler TL (2009) The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. Am J Obstet Gynecol 200(5):580.e1–580.e7CrossRef
16.
Zurück zum Zitat Urwitz-Lane R, Ozel B (2006) Sexual function in women with urodynamic stress incontinence, detrusor overactivity, and mixed urinary incontinence. Am J Obstet Gynecol 195(6):1758–1761PubMedCrossRef Urwitz-Lane R, Ozel B (2006) Sexual function in women with urodynamic stress incontinence, detrusor overactivity, and mixed urinary incontinence. Am J Obstet Gynecol 195(6):1758–1761PubMedCrossRef
17.
Zurück zum Zitat Aschkenazi SO, Rogers RG, Beaumont J, Botros SM, Sand PK, Goldberg RP (2010) A valid form of the PISQ-12, the PISQ-9, for use in comparative studies of women with and without pelvic organ prolapse and/or urinary incontinence. Female Pelvic Med Reconstr Surg 16(4):218–223PubMedCrossRef Aschkenazi SO, Rogers RG, Beaumont J, Botros SM, Sand PK, Goldberg RP (2010) A valid form of the PISQ-12, the PISQ-9, for use in comparative studies of women with and without pelvic organ prolapse and/or urinary incontinence. Female Pelvic Med Reconstr Surg 16(4):218–223PubMedCrossRef
18.
Zurück zum Zitat Arleo EK, Tal MG (2008) Fibroid-induced acute urinary retention: treatment by uterine artery embolization. Int Urogynecol J Pelvic Floor Dysfunct 19(1):161–165PubMed Arleo EK, Tal MG (2008) Fibroid-induced acute urinary retention: treatment by uterine artery embolization. Int Urogynecol J Pelvic Floor Dysfunct 19(1):161–165PubMed
Metadaten
Titel
The effect of uterine fibroid embolization on lower urinary tract symptoms
verfasst von
David Shveiky
Cheryl B. Iglesia
Danielle D. Antosh
Bela I. Kudish
Joanna Peterson
Chun-Chin Huang
James B. Spies
Publikationsdatum
01.08.2013
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 8/2013
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-012-2013-7

Weitere Artikel der Ausgabe 8/2013

International Urogynecology Journal 8/2013 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.